The Netherlands Solved the Back Door. Now Big Tobacco Is Using the Front

For decades, the Netherlands lived with a strange contradiction. Coffeeshops could legally sell cannabis over the counter, but they had no legal way to buy it. Growers stayed criminal, supply came through the shadows, and everyone called it the “back door problem.” The regulated coffeeshop experiment, known as the Wietexperiment, was supposed to fix that by building a clean, closed supply chain.

Now a different door is swinging open. Cronos Group, a Canadian cannabis company that is about 41 percent owned by Altria, the U.S. tobacco company behind Philip Morris USA and Marlboro, agreed in December 2025 to buy CanAdelaar, the experiment’s biggest grower. Dutch Health Minister Sophie Hermans has told Parliament the government cannot stop it.

What Is the Dutch Cannabis Experiment, and Why Does the Supply Chain Matter?

The Wietexperiment, formally the Controlled Cannabis Supply Chain Experiment, was enacted in 2020 to test something the Netherlands had never tried: a fully regulated, closed cannabis supply chain. The experimental phase launched on April 7, 2025, and is scheduled to run for four years, with an option to extend it by up to 18 months.

The setup is narrow. Ten municipalities take part. The 72 coffeeshops in those areas can no longer buy from the old tolerated market. They must source cannabis only from one of ten licensed growers. Import and export are banned, growers cannot sell to each other, and supply to shops outside the participating towns is prohibited.

That closed structure is the whole point. By naming the growers and controlling the flow of product, the government wanted to see whether a regulated chain could improve quality control, cut crime, and answer the back door question that tolerance policy never could. The supply chain is not a side detail here. It is the experiment.

Which is exactly why the question of who owns those ten growers carries so much weight. Control the licensed supply, and you sit at the center of the only legal cannabis market of its kind in Europe.

How Did Marlboro’s Owner End Up Inside the Dutch Cannabis Supply Chain?

The path runs through Canada. Altria bought close to half of Cronos Group in 2019 and today holds roughly 41 percent, making it a large minority shareholder. On December 9, 2025, Cronos announced it would acquire CanAdelaar for 57.5 million euros, about 67 million dollars, plus earnout payments tied to the grower’s 2026 and 2027 results.

CanAdelaar is not a minor player. Founded in 2018 and based in Voorne aan Zee, it runs a 540,000 square foot greenhouse, produces around 20,000 kilograms of dried flower a year, and is the only industrial-scale greenhouse cultivator among the ten licensed growers. It sells to nearly all 72 coffeeshops in the experiment. Revenue reached 47.3 million dollars in the twelve months ending September 30, 2025, up from 17.7 million a year earlier.

So the deal hands a tobacco-linked company the leading share of the experiment’s most productive grower. Cronos and CanAdelaar say they operate independently and that Cronos “is not a tobacco company.” Reporting by NU.nl, Investico and De Groene Amsterdammer noted that four of Cronos’s seven board members have worked at or for Altria. Readers can judge how much distance that leaves between Marlboro capital and the flower reaching Dutch shelves.

Why Can the Dutch Government Not Simply Block Tobacco-Linked Capital?

Because the rulebook was never written to ask the question. Responding to twelve parliamentary questions from CDA members Krul and Van den Brink, Minister Hermans stated plainly that the legal framework for the experiment contains no provision excluding participation based on the background of a grower’s shareholders.

Designated growers, the cabinet says, are responsible for their own ownership structure, just like any other Dutch company. There is no clause that lets ministers weigh a buyer’s industry against the experiment’s health goals. So the government cannot block the ownership transfer, regardless of who the new owner is.

The cabinet went further. It declined to investigate how often tobacco money already flows into the cannabis market, saying no such information is collected. It also ruled out tightening the rules, arguing that existing prevention measures, an advertising ban, packaging requirements, and coffeeshop education, already offer enough protection.

There is a plain contradiction on the record. The cabinet calls the tobacco industry’s marketing and lobbying “harmful to public health” and its funding of cannabis research “highly undesirable and reprehensible.” Then it declines to add a single new safeguard. Recognizing a risk and acting on it are not the same thing, and here the government does the first without the second.

What Does the Bibob Act Cover, and What Does It Miss?

The government’s one answer is the Bibob Act. Every designated grower is screened every two to three years under this law, and a change in ownership, such as the Cronos deal, can trigger a fresh review. The ultimate consequence of a negative outcome is losing the grower designation.

Here is the problem. Bibob is a criminal-integrity tool. It examines whether a business risks being used for criminal proceeds or illicit activity — in other words, whether the money is dirty. What it does not examine is whether the owner brings tobacco-sector lobbying experience, product strategy built around repeat consumption, or commercial incentives that cut against a health-led trial.

A company can pass Bibob cleanly and still carry everything public-health officials say they worry about. Marlboro capital is not criminal proceeds. Tobacco lobbying expertise is legal. Funding favorable research is legal. None of it shows up in a background check.

That gap is the whole story. A criminal-integrity review is not a conflict-of-interest policy. Leaning on Bibob to answer a public-health question is like using a metal detector to test water quality. The tool works fine. It just measures the wrong thing.

Why Does the WHO Tobacco Treaty Not Apply Here?

Article 5.3 of the WHO Framework Convention on Tobacco Control exists precisely to shield public-health policy from tobacco-industry interference. It would be the obvious instrument to reach for. The cabinet says it does not apply.

The reasoning is technical. Cannabis produced in the experiment still falls under the Opium Act and remains, legally speaking, an illegal product. Designated growers receive an exemption that lets them cultivate and supply it, but the product itself is not classified as legal. Because the cannabis is not a legal product, the Tobacco and Smoking Products Act and international tobacco obligations, including Article 5.3, are treated as out of scope.

Look at what that creates. Cannabis is regulated enough for government-designated companies to grow tonnes of it and supply coffeeshops under state oversight. Yet it stays illegal enough that the treaty built to keep tobacco lobbyists away from health policy cannot be applied. The same product is legal enough to industrialize and illegal enough to strip away tobacco-lobby protections.

There is an added wrinkle. The experiment permits the sale of pre-rolled joints containing tobacco, something not allowed in any other regulated cannabis market worldwide. Tobacco is already in the product. The treaty designed to manage tobacco’s influence is the one thing ruled out.

What Comes After a Background Check?

The deal is not final. Cronos and CanAdelaar extended the long stop date to September 9, 2026, partly because the Bibob review is still running. Closing depends on Dutch regulatory clearances, license confirmations, and completion of that review. So the immediate outcome still rests on the very tool that measures the wrong risk.

The cabinet says it is reassured about the longer term. It rates the risk of tobacco interests shaping post-experiment policy as “small,” because future decisions will lean on an independent research consortium of the WODC, Breuer&Intraval, RAND Europe and the Trimbos Institute. Independent research is a genuine strength. It is also not the same as governing who owns the supply chain while the experiment runs.

If the Netherlands wanted real safeguards, the tools are not exotic. Ownership transparency rules could require disclosure of ultimate beneficial owners and their industry ties. Lobbying limits could restrict how licensed growers and their parents engage policymakers. Research-independence conditions could bar reliance on industry-funded studies, which the cabinet already says it rejects in principle. Product-development safeguards could address exactly the vape-plus-flower double model that addiction experts flagged. Competition policy could prevent one owner from dominating the licensed market.

None of that requires banning large investors. It requires deciding that ownership is a health question, not just an integrity question.

Time to Ask a Different Question

The Netherlands spent decades trying to close the back door. The Wietexperiment was the answer, a clean supply chain built to prove regulation could work. The irony is hard to miss: the trial designed to formalize a community-rooted Dutch model may end up handing its most productive grower to a company part-owned by a Virginia cigarette giant.

The government evaluates the experiment in the coming period. That review should not stop at whether the supply chain functions. It should ask who owns it, and whether a criminal background check is really the only filter a health-led experiment gets.

The deeper lesson reaches past the Netherlands. As cannabis regulation spreads across Europe and North America, every new market will face the same pressure from well-capitalized players looking for a legal foothold. Deciding now whether ownership transparency, lobbying limits, and research independence belong in the rulebook is far easier than retrofitting them after the capital has already landed.

The back door took decades to close. The front door is open right now.

Frequently Asked Questions

---

• The Netherlands Expands Cannabis Initiative to Eight More Cities
• Event Spotlight – King’s Day: The Ultimate Orange Out in the Netherlands
• Dutch Treat Cannabis Strain
• Breeding the Culture: Henk van Dalen and Dutch Passion
• Is Microdosing Psilocybin as Therapeutic as Recent Headlines Suggest? Traditional Research Provides Mixed Results